<SEC-DOCUMENT>0001104659-21-045174.txt : 20210401
<SEC-HEADER>0001104659-21-045174.hdr.sgml : 20210401
<ACCEPTANCE-DATETIME>20210401070122
ACCESSION NUMBER:		0001104659-21-045174
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210401
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210401
DATE AS OF CHANGE:		20210401

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		21795999

	BUSINESS ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2111556d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">


<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of Report (Date of earliest event reported):</B>
April 1, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SYNTHETIC BIOLOGICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada</FONT></TD>
    <TD STYLE="width: 2%; padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-12584</FONT></TD>
    <TD STYLE="width: 2%; padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13-3808303</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction of incorporation)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File No.)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer Identification No.)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">9605 Medical Center Drive, Suite 270</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Rockville, MD 20850</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices) (Zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: (301) 417-4364</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">N/A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section 12(b)
of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="text-align: center; vertical-align: bottom">
    <TD STYLE="width: 36%; border: black 1pt solid; padding-right: -0.9pt; padding-left: 0.9pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title of each class</B></FONT></TD>
    <TD STYLE="width: 30%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 0.9pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trading Symbol(s)</B></FONT></TD>
    <TD STYLE="width: 34%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 0.9pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name of each exchange on which registered</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: -0.9pt; padding-left: 0.9pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock, par value $0.001 per share</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 0.9pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYN</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 0.9pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NYSE American</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (17 CFR &sect;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (17 CFR &sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">Emerging
growth company </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item 7.01</B></FONT></TD>
    <TD STYLE="width: 0.1in; padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regulation FD Disclosure.</B></FONT></TD></TR>
  </TABLE>

  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 1, 2021, Synthetic Biologics, Inc. (the &ldquo;Company&rdquo;)
issued a press release announcing that enrollment has been initiated and that the first six study participants were dosed in the Company&rsquo;s
Phase 1A clinical trial (the &ldquo;Phase 1a Clinical Trial&rdquo;) of SYN-020, a recombinant bovine intestinal alkaline phosphatase formulated
for oral delivery to the small intestine. The Company also anticipates announcing topline results from this study as well as commencing
a multiple-ascending dose study of SYN-020 during the third quarter of 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A copy of the press release is furnished as Exhibit 99.1 to this Current
Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information in this Item 7.01 and&nbsp;in the press release attached
as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be &ldquo;filed&rdquo; for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities
Act of 1933, as amended. The information contained in this Item 7.01 and in the press release attached as Exhibit 99.1 shall not be incorporated
by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date
hereof, regardless of any general incorporation language in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The press release attached as Exhibit 99.1 includes &ldquo;safe harbor&rdquo;
language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein
are &ldquo;forward-looking&rdquo; rather than historical.&nbsp;The Company undertakes no duty or obligation to update or revise the information
contained in this&nbsp;Current Report on Form 8-K, although it may do so from time to time if its management believes it is appropriate.
Any such updating may be made through the filing of other reports or documents with the Securities and Exchange Commission, through press
releases or through other public disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item 8.01</B></FONT></TD>
    <TD STYLE="width: 0.1in; padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other Events.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 1, 2021, the Company issued a press release announcing that
enrollment has been initiated and that the first six study participants were dosed in the Company&rsquo;s Phase 1A Clinical Trial of SYN-020,
a recombinant bovine intestinal alkaline phosphatase formulated for oral delivery to the small intestine. The Company anticipates announcing
topline results from this study as well as commencing a multiple-ascending dose study of SYN-020 during the third quarter of 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item 9.01</B></FONT></TD>
    <TD STYLE="width: 0.1in; padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial Statements and Exhibits.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 4%; padding-right: 0.8pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="width: 89%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: left"><A HREF="tm2111556d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt"><A HREF="tm2111556d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release issued by Synthetic Biologics, Inc., dated April 1, 2021</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: April 1, 2021</FONT></TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYNTHETIC BIOLOGICS, INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 39%; padding-right: 0.8pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-right: 1.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Steven A. Shallcross</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven A. Shallcross</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0">Chief Executive Officer and Chief Financial Officer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0">&nbsp;</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2111556d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 80pt; width: 214pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>Synthetic
Biologics Announces First Six Participants Dosed in Phase 1a Clinical Trial of SYN-020 Intestinal Alkaline Phosphatase</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B><I>A
Multiple-Ascending Dose Study is on Track to Begin in Q3 2021</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B><I>Phase
1 Clinical Program Intended to Support Development of SYN-020 in Multiple Indications, </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B><I>Including
Treatment of Celiac Disease, Non-Alcoholic Fatty Liver Disease and Age-Related Metabolic </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B><I>and
Inflammatory diseases </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt; color: windowtext"><B>Rockville,
MD, April 1, 2021 &ndash;</B></FONT> <FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Synthetic Biologics, Inc.
<FONT STYLE="color: windowtext">(NYSE American: SYN),</FONT> a diversified clinical-stage company leveraging the microbiome to develop
therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, <FONT STYLE="color: windowtext">today
announced that enrollment has commenced and six study participants were dosed in a Phase 1a single-ascending dose clinical trial of SYN-020
intestinal alkaline phosphatase (&ldquo;IAP&rdquo;). </FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt; color: windowtext">SYN-020
</FONT><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">is a recombinant bovine IAP formulated for oral delivery
to the small intestine. The published literature indicates that IAP functions to diminish intestinal inflammation, tighten the gut barrier
to diminish &ldquo;leaky gut,&rdquo; and promote a healthy microbiome. Despite its broad therapeutic potential, a key hurdle to commercialization
has been the high cost of IAP manufacture. Synthetic Biologics has overcome this hurdle and has the ability to produce SYN-020 at a scale
and cost viable for clinical and commercial development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&ldquo;We
are excited about the initiation of this clinical study which is an important milestone in furthering the clinical development of SYN-020,&rdquo;
said Steven A. Shallcross, Chief Executive and Financial Officer. &ldquo;We believe SYN-020 has enormous potential to help address a
considerable unmet need for innovative new therapies targeting GI disorders stemming from immune and inflammatory responses, including
celiac disease, non-alcoholic fatty liver disease, as well as age-related metabolic and inflammatory diseases. In the U.S. alone, prevalent
cases of celiac disease are expected to increase to 4.3 million by 2023, representing a significant market opportunity for a highly differentiated
product such as SYN-020. We look forward to announcing topline results from this study as well as commencing a multiple-ascending dose
study of SYN-020 anticipated during the third quarter of 2021.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The
Phase 1a study, which is now underway at Spaulding Clinical Research, LLC of West Bend, WI, is designed to evaluate safety, tolerability
and pharmacokinetics of four single-ascending doses of oral SYN-020 in healthy volunteers. In all, up to 24 healthy adult volunteers
will be enrolled into four cohorts that will run sequentially, all of which will receive oral SYN-020. During the third quarter of 2021,
a topline data readout is expected to be reported and a multiple-ascending dose study of SYN-020 is planned to begin.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>About
Synthetic Biologics, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Synthetic
Biologics, Inc. (NYSE American: SYN) is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed
to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. The Company&rsquo;s lead candidates are: (1) SYN-004
(ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal
(GI) tract to prevent (a) microbiome damage, (b) <I>Clostridioides difficile</I> infection (CDI), (c) overgrowth of pathogenic organisms,
(d) the emergence of antimicrobial resistance (AMR), and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell
transplant (HCT) recipients, and (2) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced
under cGMP conditions and intended to treat both local GI and systemic diseases. For more information, please visit Synthetic Biologics'
website at www.syntheticbiologics.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified
by terminology such as &quot;may,&quot; &quot;should,&quot; &quot;potential,&quot; &quot;continue,&quot; &quot;expects,&quot; &quot;anticipates,&quot;
 &quot;intends,&quot; &quot;plans,&quot; &quot;believes,&quot; &quot;estimates,&quot; and similar expressions, and includes statements
regarding the SYN-020 Phase 1 trial supporting development of SYN-020 in multiple indications, SYN-020 having the potential to help address
a considerable unmet need for innovative new therapies targeting GI disorders stemming from immune and inflammatory responses, including
celiac disease, non-alcoholic fatty liver disease, as well as age-related metabolic and inflammatory diseases, the expected increase
in the number of celiac disease in the U.S., announcing topline results from the SYN-020 study as well as commencing a multiple-ascending
dose study of SYN-020 during the third quarter of 2021 and the intended benefits to be derived from SYN-004 and SYN-020. These forward-looking
statements are based on management's expectations and assumptions as of the date of this press release and are subject to a number of
risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations
and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results
to differ materially from current expectations include, among others, Synthetic Biologics' ability to develop SYN-020 in multiple indications,
the ability to announce topline results from the SYN-020 study as well as commencing a multiple-ascending dose study of SYN-020 during
the third quarter of 2021, the ability to continue to comply with continued listing requirements of the NYSE American, the ability of
its product candidates to demonstrate safety and effectiveness, as well as results that are consistent with prior results, Synthetic
Biologics' clinical trials continuing and/or beginning enrollment as expected, a failure to receive the necessary regulatory approvals
for commencement of clinical trials and commercialization of Synthetic Biologics' therapeutics, including approval of proposed trial
designs, a failure of Synthetic Biologics' clinical trials, and those conducted by investigators, for SYN-004 and SYN-020 to be commenced
or completed on time or to achieve desired results and benefits, a failure of Synthetic Biologics' clinical trials to continue enrollment
as expected or receive anticipated funding, a failure of Synthetic Biologics to successfully develop, market or sell its products, Synthetic
Biologics' inability to maintain its material licensing agreements, or a failure by Synthetic Biologics or its strategic partners to
successfully commercialize products, Synthetic Biologics&rsquo; ability to achieve acceptance of its product candidates in the marketplace
and the successful development, marketing or sale of Synthetic Biologics' products by competitors that render Synthetic Biologics' products
obsolete or non-competitive, the continued maintenance and growth of Synthetic Biologics' patent estate, Synthetic Biologics becoming
and remaining profitable, Synthetic Biologics' ability to obtain or maintain the capital or grants necessary to fund its research and
development activities, a loss of any of Synthetic Biologics' key scientists or management personnel and other factors described in Synthetic
Biologics' Form 10-K for the year ended December 31, 2020 and its other filings with the SEC, including subsequent periodic reports on
Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and Synthetic Biologics undertakes
no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise,
except as required by law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>For
further information, please contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Synthetic
Biologics, Inc. (Corporate and Investors)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Vincent
I. Perrone, Director Corporate Communication, (240) 660-2000, info@syntheticbiologics.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Ogilvy
(Media)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Gregory
Kelley, Senior Vice President, (404) 836-2302, gregory.kelley@ogilvy.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">#
# #</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #C F # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **CFFCMX6EE<*BC))KE-2U^:Z)CMRT4/M]YOK7#C<PHX.-YZOHNIO
M0P\ZS]W;N=!=ZQ9V9*M)OD'\"<FL>?Q-,Q(@A1!ZMR:P,T9KY3$9YBZK]Q\J
M\O\ -GJT\#2COJ:CZ[J+'_7[1Z!!_A31K>H@_P#'R?\ OE?\*S<T9KSWC<4W
M?VDOO9O["G_*ON-A/$5\GWC&_P#O+_A5V'Q0O2>V(]T;/Z&N:S1FNBEFV-I[
M5&_74B6$HR^R=U;:K9W>!'.H8_PMP:N5YSFM&RUN[L\+O\V/^X_/Y'M7M87B
M)-\N(C;S7^7^1QU<N>]-_>=K15#3]6MM0&$;9+WC;K^'K5^OHZ56%6*G3=T>
M;.$H/EDK,****T)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***:)$:1HP
M<LH!8>F>E%P'4UW6-&=V"JHR2>PIU<UXHU$J%L8VZC=)CT[#^OY5S8S$QPU%
MU9=/Q?0VH4G5FH(S=6U9]1G(4E8%/R+Z^YK-W4S-&:_/ZU6=>HZE1W;/HH4X
MPBHQV'[J-U,S1FLK%V'[J-U,S1FBP6'[J-U,S1FBP6'[J-U,S1FBP6)%<JP9
M6((Y!!Z5TVD>(1(5M[U@&/"R]C]?\:Y7-&:Z\'C*N$GS4WIU71F-;#PK1M(]
M,HKF/#^M\K973]>(G/\ (_TKIZ^ZPF+IXJFJD/FNS/ KT949\L@HHHKI,0HH
MHH **** "BBB@ HHHH **** "BJ-_K6E:7C^T-2M+4GH)IE0G\":S5\=>%6;
M:-?L,^\P _.G9A<Z"BJUGJ-CJ,?F6-[;W2#^*"57'Y@U9I %%%% !1110 44
M44 %%%% !1110 4444 %%%% !115;4;EK/3+NZ10S0PO( >A(4G^E %FBO#?
M^%XZO_T";'_OI_\ &C_A>.K_ /0)L?\ OI_\:OV<B>='N5%5M.N6O-,M+IU"
MM-"DA Z E0?ZU9J"@HHHH **** "BBB@ HHHH **** "BBO,O'7Q,U#PIXC.
MFVUA;3Q^2LF^0MG)SZ'VII-Z(3=CTVBO*?!WQ5U+Q)XJLM)GT^UBBN-^YXRV
MX;49N,G_ &:]6H::W!-/8****0PHHHH **** "BBB@"GJ=^FFV3SMRW1%_O-
M4&A*YTT7$IS+<,9&)_(?H!7+>(=2^W:BR(?W,.47W/<UVUG$(;*"(?P1JOY"
MO*PV(^LXN;7PP5EZO=_A8[JU'V-"-]Y$K,$1F8X51DFO-[NY:[NY;ANLC$X]
M!V%=SKDWD:+=/GDIM_,X_K7GN:\WB"JW*%+Y_H=>5T_=E/Y#\T9IF:,U\[8]
M6P_-&:9FMGP_I(U*X:2;/V>+&1_>/I6M##SKU%3ANR*LXTX.<MD4+>RNKO\
MU$$D@]57C\Z?/IM[;)OFM954=6VY KT-$2- B*%51@ # %.KZ-</4^76;O\
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MZ;;Z/I5KIUJ@6&WC"* .N.I/N3S^-5*7*M!17-N?+NM^%]:\.,@U;3Y+8/\
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M?4E?(>H_\A.[_P"NS_\ H1KZ\KY%U6-HM8O8W&&2XD4CW#&II=1U#V'X%_\
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MS)U$3C."1Z'.#^%4V[71*6MF9G_"LO&/_0$D_P"_T?\ \51_PK+QC_T!)/\
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M?:-\PBV^9LQD$YS@^E6=#U3^VM'@U#R?)\W=^[W;L88KUP/2N>^)7_(N6_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $90P(8 @]0:S;C
MP]HUR29=,M2QZL(PI/XBM.BIE&,MU<N%2<-8MKT9SK^!O#SG/V J2<_+,_\
MC0G@;P\C9^PEL=FF?'\ZZ*BL_J]+^5?<;?7<3M[1_>RA::)I=B0UM86\;#^(
M1C=^?6K]%%:J*BK)&$IRF[R=PHHHIDA1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
B4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
